8-K ·Filed Jun 12, 2026

REX

REX AMERICAN RESOURCES Corp
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0000930413-26-001847
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine adoption of a compensation template with no immediate market signal. Traders should monitor future 10-Q or 8-K filings for actual RSU grants under this plan if they want to assess potential dilution. No action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
REX ▲ +7.19% at T+20d
NEUTRAL call ✓ call won +7.19% · α vs SPY +5.41% · entry $43.94 → $47.10
Next anchor: T+60d due 23d ago
Latest observation: T+57 -10.19% FF3 residual α
Entry anchored
Jun 12, 10:30 AM ET
via exchange tick
T+1d
-2.21%
call -2.21% · α -3.97%
$42.97
settled 4mo ago
T+5d
-0.23%
call -0.23% · α -0.90%
$43.84
settled 3mo ago
T+20d
+7.19%
call +7.19% · α +5.41%
$47.10
settled 3mo ago
T+60d
—
call — · α —
—
due 23d ago

Price Chart

Loading chart...

Executive Summary

REX American Resources filed an 8-K on June 10, 2026, disclosing that its Compensation Committee approved the form of a Restricted Stock Unit (RSU) Award Agreement under the company's 2026 Incentive Plan. This is a routine administrative adoption of a compensation plan template for future performance-based equity grants — no officers were appointed or departed, and no specific awards or financial amounts were disclosed.

Key Facts

  • Compensation Committee approved a form of RSU Award Agreement under the 2026 Incentive Plan on June 10, 2026.
  • The agreement provides for performance-based vesting RSUs tied to achievement of an undisclosed performance objective.
  • No director/officer changes, no specific grant amounts, and no named grantees in the filing.
  • The filing is a standard compensatory plan disclosure under Item 5.02 with no material financial impact.

Financial Impact

No financial impact disclosed; form agreement only, no specific awards or dollar amounts.

Market Snapshot

Exchange
NYSE
Sector
Industrial Organic Chemicals
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000930413-26-001847
Document: c116671_8k-ixbrl.htm0000930413-26-001847
Document: 0000930413-26-001847-index-headers.html0000930413-26-001847
Document: 0000930413-26-001847-index.html0000930413-26-001847
Document: 0000930413-26-001847.txt0000930413-26-001847
8 reports for REX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for REX — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BULLISH ★ 7/10
$42.80 $41.62▼ −2.76%▼ −3.80%$43.37 (+1.33%)
Jul 1, 2026
13w ago
8-K
NEUTRAL ★ 3/10
$45.50 $44.98▼ −1.14%▼ −1.01%$43.37 (−4.68%)
Jun 12, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$43.94 $42.97▼ −2.21%▼ −3.97%$43.37 (−1.30%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$43.00 $43.94▲ +2.19%▲ +1.65%$43.37 (+0.86%)
Jun 10, 2026
16w ago
Insider Cluster
NEUTRAL ★ 4/10
$43.83 $43.00▼ −1.89%▼ −3.59%$43.37 (−1.05%)
Jun 3, 2026
17w ago
8-K
NEUTRAL ★ 3/10
$46.28 $46.00▼ −0.60%▼ −1.00%$43.37 (−6.29%)
May 28, 2026
18w ago
8-K
MIXED ★ 5/10
$48.26 $46.76▼ −3.11%▼ −3.35%$43.37 (−10.13%)
Apr 15, 2026
24w ago
DEFA14A
NEUTRAL ★ 4/10
$43.11 $43.57▲ +1.07%▲ +0.81%$43.37 (+0.60%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (64h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access